As a cell surface marker for cancer stem cells, CD44 ablation weakens the glycolytic phenotype of p53-deficient or hypoxic CRC cells and decreases metabolic flux to the PPP and glutathione (GSH) levels, which in turn increases the chemotherapy sensitivity of CRC cells [95]. This evidence concerns the gene CD44 and colorectal carcinoma.